At noon on March 29th, the Lifetech Satellite Association invited Academician Runlin Gao from Chinese Academy of Medical Sciences and Fuwai Hospital, Professor Daxin Zhou from Zhongshan Hospital Affiliated to Fudan University to serve as hosts. And it also invited Professor Yumei Xie from Guangdong People's Hospital, Professor Bo Xu and Professor Jianhua Lu from Chinese Academy of Medical Sciences and Fuwai Hospital, Professor Gang Wu from Wuhan University People's Hospital, and Dr. David Zhang, Chairman of Biotyx, to serve as speakers. They jointly conducted academic reports and exchange discussions on a number of innovative products.
(Academician Gao Runlin and Professor Daxin Zhou presided over the association)
The satellite association attracted experts and scholars from all over the country to attend, as well as many foreign experts. The meeting was full.
（Meeting venue）
Professor Bo Xu, Fuwai Hospital, Chinese Academy of Medical Sciences:
Professor Bo Xu made a report titled "Prospective, Single-center clinical Trial to Evaluate the Safety and Feasibility of IBS Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System First-in-Man Treatment of Coronary Artery Stenosis ". Biotyx's IBS®™ Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold is the only fully degradable vascular scaffold in the world that uses iron as a material, and is currently the only fully degradable scaffold with a thin wall design. Professor Xu announced the latest progress of the IBS-FIM study. The study currently implants 57 cases worldwide. Fuwai Hospital has completed a total of 45 single-center studies, of which 2 cases were broadcast live at the 2018 CIT conference. No adverse events occurred. In the future, with the accumulation of clinical experience and a large amount of relevant data, it will further prove the safety and effectiveness of IBS®™ sirolimus-eluting iron bioresorbable coronary scaffolds.
（Professor Bo Xu speech scene）
Dr. David Zhang, Chairman of Biotyx:
Dr. David Zhang detailed the product layout of Biotyx for everyone from three aspects: the company's basic situation, cardiovascular intervention product innovation and cardiovascular material innovation. Dr. Zhang introduced in his speech that Biotyx invests 20% of sales revenue in R & D and innovation, because innovation is regarded as the company's core concept, and adheres to a differentiated product development strategy. The company's products currently under research and sales have the status of filling gaps in China and even the world. Dr. Zhang finally emphasized: "We don't make infringing products, don't make me-too products, we must make innovative products", which won the unanimous appreciation of the experts present.
（Dr. David Zhang speech scene）
At this most influential interventional cardiology conference in China, the innovative products independently developed by Biotyx Medical (Shenzhen) Co., Ltd. were perfectly presented at the conference. Its IBS®™ sirolimus-eluting iron bioresorbable coronary scaffold system was obtained wide recognition and high praise from industry experts.
In the future, Biotyx will continue to insist on independent innovation, create safer and more effective innovative products, and work with industry experts to build a great dream of human health.
